GGrantIndex
← Leaderboards

Wonder P. Drake

University Of Maryland Baltimore

$8,520,284
Attributed
$11,103,534
Total exposure
11
Grants
10
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.2M · FY200525
$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$11,103,534 · 11

By mechanism

R01$8,252,981 · 4
K24$1,100,779 · 1
R56$857,679 · 1
U01$463,022 · 1
R21$426,194 · 1
M01$2,879 · 3

Top collaborators

Most similar at University Of Maryland Baltimore

Same institution · by research overlap

Others in their field

Top investigators on “Sarcoidosis

Research focus

SarcoidosisLungT-LymphocyteGranulomatousPeripheral Blood Mononuclear CellMolecularResponseInvestigationPathogenesisUniversitiesImmunologicsSpecimenMycobacterialCd4 Positive T LymphocytesTuberculosisEtiologyCytokinePulmonary SarcoidosisMycobacterium TuberculosisGenus MycobacteriumImmuneCommunicable DiseasesFoundationsProduction

Grant awards (46)

Mentoring in Translational Research in Interstitial Lung Diseases$113,963
K24 · FY2025 · HL · contact PI
Mentoring in Translational Research in Interstitial Lung Diseases$113,963
K24 · FY2024 · HL · contact PI
Mentoring in Translational Research in Interstitial Lung Diseases$113,963
K24 · FY2023 · HL · contact PI
Mentoring in Translational Research in Interstitial Lung Diseases$113,963
K24 · FY2022 · HL · contact PI
Mentoring in Translational Research in Interstitial Lung Diseases$113,931
K24 · FY2022 · HL · contact PI
Investigation of sex variation in PD-1/pSTAT3/IL-17A signaling in sarcoidosis pathogenesis$857,679
R56 · FY2020 · HL · contact PI
Serial, non-invasive molecular analysis of exhaled breath condensate to define the pulmonary flora in critically injured, ventilated adults$150,146
R01 · FY2020 · GM · contact PI
Mentoring in Translational Research in Interstitial Lung Diseases$105,606
K24 · FY2020 · HL · contact PI
Mentoring in Translational Research in Interstitial Lung Diseases$105,768
K24 · FY2019 · HL · contact PI
Serial, non-invasive molecular analysis of exhaled breath condensate to define the pulmonary flora in critically injured, ventilated adults$312,050
R01 · FY2018 · GM · contact PI
Mentoring in Translational Research in Interstitial Lung Diseases$106,057
K24 · FY2018 · HL · contact PI
Microbial induction of sarcoidosis CD4+ T cell dysfunction$792,506
R01 · FY2017 · HL · contact PI
Serial, non-invasive molecular analysis of exhaled breath condensate to define the pulmonary flora in critically injured, ventilated adults$312,050
R01 · FY2017 · GM
Mentoring in Translational Research in Interstitial Lung Diseases$106,624
K24 · FY2017 · HL · contact PI
Microbial induction of sarcoidosis CD4+ T cell dysfunction$757,536
R01 · FY2016 · HL · contact PI
Serial, non-invasive molecular analysis of exhaled breath condensate to define the pulmonary flora in critically injured, ventilated adults$312,050
R01 · FY2016 · GM
Mentoring in Translational Research in Interstitial Lung Diseases$106,941
K24 · FY2016 · HL · contact PI
Microbial induction of sarcoidosis CD4+ T cell dysfunction$397,124
R01 · FY2015 · HL · contact PI
Microbial induction of sarcoidosis CD4+ T cell dysfunction$375,301
R01 · FY2015 · HL · contact PI
Serial, non-invasive molecular analysis of exhaled breath condensate to define the pulmonary flora in critically injured, ventilated adults$310,075
R01 · FY2015 · GM
Microbial induction of sarcoidosis CD4+ T cell dysfunction$21,972
R01 · FY2015 · HL · contact PI
Microbial induction of sarcoidosis CD4+ T cell dysfunction$731,710
R01 · FY2014 · HL · contact PI
Investigation of microbial hetergeneity to sarcoidosis and AAT clinical outcome$149,999
U01 · FY2014 · HL · contact PI
Microbial induction of sarcoidosis CD4+ T cell dysfunction$4,430
R01 · FY2014 · HL · contact PI
Microbial induction of sarcoidosis CD4+ T cell dysfunction$689,550
R01 · FY2013 · HL · contact PI
Investigation of microbial hetergeneity to sarcoidosis and AAT clinical outcome$145,795
U01 · FY2013 · HL · contact PI
Investigation of microbial hetergeneity to sarcoidosis and AAT clinical outcome$167,228
U01 · FY2012 · HL · contact PI
Investigation of the role of bacteria in the sarcoidosis trimolecular complex$372,498
R01 · FY2009 · HL · contact PI
Role of mycobacteria in sarcoidosis immunopathogenesis$364,415
R01 · FY2009 · AI · contact PI
Role of mycobacteria in sarcoidosis immunopathogenesis$40,646
R01 · FY2009 · AI · contact PI
Investigation of the role of bacteria in the sarcoidosis trimolecular complex$373,077
R01 · FY2008 · HL · contact PI
Role of mycobacteria in sarcoidosis immunopathogenesis$364,456
R01 · FY2008 · AI · contact PI
Investigation of the role of bacteria in the sarcoidosis trimolecular complex$8,277
R01 · FY2008 · HL · contact PI
RESPONSE TO BACTERIAL ANTIGENS BY SARCOIDOSIS PATIENTS$35
M01 · FY2008 · RR · contact PI
Investigation of the role of bacteria in the sarcoidosis trimolecular complex$372,976
R01 · FY2007 · HL · contact PI
Role of mycobacteria in sarcoidosis immunopathogenesis$371,331
R01 · FY2007 · AI · contact PI
RESPONSE TO BACTERIAL ANTIGENS BY SARCOIDOSIS PATIENTS$746
M01 · FY2007 · RR · contact PI
Role of mycobacteria in sarcoidosis immunopathogenesis$407,734
R01 · FY2006 · AI · contact PI
Investigation of the role of bacteria in the sarcoidosis trimolecular complex$395,872
R01 · FY2006 · HL · contact PI
Investigation of the role of bacteria in the sarcoidosis trimolecular complex$9,079
R01 · FY2006 · HL · contact PI
Investigation of the role of bacteria in the sarcoidosis trimolecular complex$6,120
R01 · FY2006 · HL · contact PI
RESPONSE TO BACTERIAL ANTIGENS BY SARCOIDOSIS PATIENTS$2,098
M01 · FY2006 · RR · contact PI
Molecular analysis of frozen sarcoidosis granulomas$192,971
R21 · FY2005 · HL
Molecular analysis of frozen sarcoidosis granulomas$4,384
R21 · FY2005 · HL
Molecular analysis of frozen sarcoidosis granulomas$2,339
R21 · FY2005 · HL
Molecular analysis of frozen sarcoidosis granulomas$226,500
R21 · FY2004 · HL